- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04952155
Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
August 11, 2021 updated by: Peking University Third Hospital
A Single-center, Open-label Clinical Study to Evaluate the Efficacy and Safety of Low-dose IL-2 in the Treatment of Immune-associated ALS Syndrome
The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome.
Study Overview
Detailed Description
This is a single-center, open-label, self-controlled clinical study with a sample size of 10 patients for 48 weeks, including 24 weeks of administration, and 24 weeks of follow-up.
During the administration period, medication was given for 2 weeks and rest for 2 weeks, as a course of treatment, with a total of 6 courses for 24 weeks.
During the administration period, the drug was given on alternate days, and IL-2 1mIU was subcutaneously injected the next day for 7 times, and then rested for 2 weeks, and the cycle was repeated for 6 times.
The primary outcome index was the change in the rate of ALSFRS-R score between administration period and follow-up period.
Secondary outcome measures included changes in the rate of ALSAQ-40 score, ROADS score, MRC score, survival time, FVC%, Treg and CD4+ T cell subsets, inflammatory factors, serum and cerebrospinal fluid NFL during follow-up versus administration , changes in the inhibition function of Treg; Exploratory outcome indicators included the change degree of compound muscle action potential (CMAP) amplitude, quantitative analysis of corneal nerve morphologic changes by corneal confocal microscopy (CCM), Treg single-cell sequencing transcriptome analysis.
The related safety indexes were also evaluated.
Study Type
Interventional
Enrollment (Anticipated)
13
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100098
- Recruiting
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-70 years old;
- Clinically diagnosed with ALS syndrome, i.e., with ALS -like manifestations, consisting of a combination of upper and/or lower motor neuron damage;
- significant abnormalities with rheumatoid immune-related indicators, or diagnoses of immune-mediated ALS syndrome, including but not limited to multifocal motor neuropathy (MMN), Lewis-Sumner syndrome, and other ALS-like syndromes with an immune background that cannot be clearly classified;
- Poor treatment with conventional hormones or gamma globulin;
- Permitted concomitant treatment: oral prednisone or equivalent doses of other glucocorticoids (≤1.0mg/kg/d); Oral routine dose of immunosuppressants or immunomodulators, such as cyclophosphamide, tacrolimus, etc.; Routine oral doses such as too much force; Doses and types of accompanying therapeutic drugs should not be changed from the trial enrollment to the end of follow-up.
- For women of reproductive age, contraception for at least 2 weeks at the time of enrolment and negative urine HCG;
- Reasonable and effective contraceptive measures should be taken by subjects of childbearing age from the time of trial enrollment to the end of follow-up;
- Signed informed consent.
Exclusion Criteria:
- Allergic or intolerance to IL2;
- Receive non-standard treatment or use of excessive dose of glucocorticoids or gamma globulin intravenously within 2 months before enrollment;
- Vaccination within 6 months before enrolment or between enrolment and the end of follow-up;
- Peripheral venous white blood cells < 2000/mm3, lymphocytes < 600/mm3, platelets < 80,000 /mm3;
- Complicated with severe infection or inflammation, such as bacteremia, sepsis, etc.;
- Complicated blood system diseases, infectious diseases (hepatitis, HIV, tuberculosis, etc.), mental diseases, dementia, severe hypotension, substance abuse history, malignant tumor history, organ transplantation history, etc.;
- Severe liver, kidney, lung or heart dysfunction: heart failure (≥NYHA grade III), renal insufficiency (creatinine clearance ≤30ml/min), abnormal liver function (3 times the upper limit of normal >);
- Pregnant and lactating women;
- Currently participating in other clinical studies or using other investigational drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IL-2
The administration period was divided into 6 courses.
6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
|
The administration period was divided into 6 courses.
6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
The adminstration course was 24 weeks..
The 24-week follow-up period was followed after the treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALSFRS-R score
Time Frame: week 0,week 24 and week 48
|
Changes in the rate of ALSFRS-R score during administration period compared with follow-up period
|
week 0,week 24 and week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALSFRS-R score
Time Frame: week 0,week 24 and week 48
|
Changes in the slope of ALSFRS-R score during adminstration period compared with the follow-up period
|
week 0,week 24 and week 48
|
ROADS score
Time Frame: week 0,week 24 and week 48
|
Changes in the rate of ROADS score during adminstration period compared with the follow-up period
|
week 0,week 24 and week 48
|
ALSAQ-40 score
Time Frame: week 0,week 24 and week 48
|
Changes in the rate of ALSAQ-40 score during adminstration period compared with the follow-up period
|
week 0,week 24 and week 48
|
MRC score
Time Frame: week 0,week 24 and week 48
|
Changes in the rate of ALSAQ-40 score during adminstration period compared with the follow-up period
|
week 0,week 24 and week 48
|
Immunological Responses
Time Frame: week 0 and week 24
|
Analysis regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells,Teff cells,follicular helper T (Tfh) cells and related cytokines before and during IL-2 treatment.
|
week 0 and week 24
|
NFL in the serum and cerebrospinal fluid
Time Frame: week 0,week 24 and week 48
|
week 0,week 24 and week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ANTICIPATED)
December 31, 2021
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
June 27, 2021
First Submitted That Met QC Criteria
June 27, 2021
First Posted (ACTUAL)
July 7, 2021
Study Record Updates
Last Update Posted (ACTUAL)
August 18, 2021
Last Update Submitted That Met QC Criteria
August 11, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M2020420
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on IL-2
-
Brigham and Women's HospitalTerminatedAbdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; DeformityUnited States
-
Peking University People's HospitalUnknown
-
jiangjingtingUnknownLymphoma, B CellChina
-
University of ChicagoTerminatedMetastatic Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMelanoma | Neoplasm MetastasisUnited States
-
National Cancer Institute (NCI)CompletedNon Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
University of MinnesotaCompleted
-
National Cancer Institute (NCI)TerminatedSarcoma | Breast Neoplasm | Lung Neoplasm | Kidney NeoplasmUnited States
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletedHealthy VolunteersFrance
-
Iovance Biotherapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States